BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BIFI -  - Institute for Biocomputation and Physics of Complex Systems - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://bifi.es
X-WR-CALDESC:Events for BIFI -  - Institute for Biocomputation and Physics of Complex Systems
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Madrid
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Madrid:20261009T123000
DTEND;TZID=Europe/Madrid:20261009T140000
DTSTAMP:20261009T005757
CREATED:20261008T100105Z
LAST-MODIFIED:20261008T100105Z
UID:10865-1791549000-1791554400@bifi.es
SUMMARY:BIFI TALK: Andrea Ilari\, Istituto di Biologia e Patologia Molecolari\, IBPM of CNR  c/o Dip. Scienze Biochimiche Università Sapienza\,Roma
DESCRIPTION:[vc_row][vc_column][vc_column_text css=”.vc_custom_1791453588217{margin-bottom: 0px !important;}”]BIFI TALK: Andrea Ilari\, Istituto di Biologia e Patologia Molecolari\, IBPM of CNR  c/o Dip. Scienze Biochimiche Università Sapienza\, P.le Aldo Moro 5\, 00185 Roma \nTítulo: Exploiting a Druggable E2 Ubiquitin Conjugating Enzyme and an E3 Ligase for PROTAC-Mediated Degradation of Trypanothione Reductase in Leishmania \nAbstract \nLeishmaniasis is a neglected tropical disease affecting up to one million people annually according to the World Health Organization. Visceral leishmaniasis\, caused by Leishmania infantum\, is the most severe form of the disease and can be fatal if left untreated. Current therapies are limited by toxicity\, variable efficacy\, lengthy treatment regimens\, and the emergence of drug resistance [1]. \nThe parasite survives the oxidative burst generated by host macrophages through a unique trypanothione-based redox system\, whose central enzyme\, trypanothione reductase (TR)\, maintains trypanothione in its reduced state. Owing to its essential role in parasite survival\, absence in humans\, and favorable druggability profile\, TR has long been considered an attractive therapeutic target. However\, despite decades of research\, no TR inhibitors have advanced to clinical development\, mainly because of insufficient efficacy and safety concerns [2]. \nTargeted protein degradation has recently emerged as an alternative therapeutic strategy capable of eliminating\, rather than inhibiting\, disease-relevant proteins. PROteolysis TArgeting Chimeras (PROTACs) are bifunctional molecules that induce ubiquitination and subsequent proteasomal degradation of a target protein by recruiting components of the ubiquitin–proteasome system (UPS) [3]. As first step\, we developed TR-targeting PROTACs designed to recruit a putative Leishmania E3 ligase\, but their activity was modest and the recruited E3 remains poorly characterized. To overcome these limitations\, we propose an innovative E2-recruiting PROTAC strategy that bypasses the requirement for a defined E3 ligase. As a first step\, we structurally and functionally characterized a Leishmania major ubiquitin-conjugating enzyme (E2). Crystallographic fragment screening identified potential ligandable sites on the enzyme\, while DeepFrag-guided fragment expansion and AutoDock Vina docking were employed to generate and prioritize E2-binding chemotypes. Together\, these studies establish the molecular framework for the rational development of E2-recruiting PROTACs targeting TR and open new opportunities for exploiting the ubiquitin–proteasome system in antileishmanial drug discovery [4]. \nReferences \n[1] S. Pradhan\, R. A. Schwartz\, A. Patil\, S. Grabbe\, and M. Goldust\, Clin Exp Dermatol\, 2022\, 47\, 516.\n[2] T. Battista\, G. Colotti\, A. Ilari\, and A. Fiorillo\, Molecules\, 2020. 25\, 1924.\n[3] S. Gu\, D. Cui\, X. Chen\, X. Xiong\, and Y. Zhao\, BioEssays\, 2018\, 40\, e1700247.\n[4] C. Exertier\, L. Antonelli\, A. Liuzzi\, M. Ruffa\, V. Brufani\, G. Colotti\, A. Fiorillo\, A. Ilari; ACS Omega 2026; https://doi.org/10.1021/acsomega.6c05158[/vc_column_text][/vc_column][/vc_row]
URL:https://bifi.es/schedule/bifi-talk-andrea-ilari-istituto-di-biologia-e-patologia-molecolari-ibpm-of-cnr-c-o-dip-scienze-biochimiche-universita-sapienzaroma/
LOCATION:Edificio Institutos I+D\, Mariano Esquillor\, 50018 Zaragoza\, Zaragoza\, Zaragoza\, 50018\, España
CATEGORIES:Events
END:VEVENT
END:VCALENDAR